

## Peer Review File

Article information: <https://dx.doi.org/10.21037/acr-23-86>

### Reviewer A

#### Comment 1

Abstract:

Revise the grammatical error: This is thought to account for its poor median survival of two to eleven years months.

Revise the grammatical error in the Key findings: Choroidal metastasis of pancreatic adenocarcinoma are rare.

#### Reply 1

We have updated the wording to correct the grammatical errors in the Abstract and Key Findings sections.

#### Changes in the text

Abstract: “This is thought to account for its poor median survival of two to eleven months”. (p.2, line 59)

Key Findings: “Choroidal metastasis of pancreatic adenocarcinoma is rare” (p. 3, highlight box)

#### Comment 2

Introduction:

Add a reference for the CARE checklist.

#### Reply 2

We have added a citation to the References for the CARE checklist. We reference the CARE checklist in the introduction in the following text: “We report a case of pancreatic adenocarcinoma with distant metastasis to the left choroid in accordance with the CARE reporting checklist.”

#### Changes in the text

Introduction:

“We report a case of pancreatic adenocarcinoma with distant metastasis to the left choroid in accordance with the CARE reporting checklist [6].” (p. 3, line 81)

References:

6. CARE checklist. <https://www.care-statement.org/checklist>. Published 2013.

[Accessed 2023](#)

(p.8, line 204)

### Comment 3

References:

Revise formatting: If a report has more than three authors, the first three authors should be listed, followed by “et al.”

### Reply 3

We have updated the References to follow this formatting guideline. (p.8-9).

### Comment 4

Appendix:

Figure 1, 2 and 3: pictures are named in capital letters but in the caption, they are mentioned in lower-case letters.

Page 14 is indicated as 2-1 instead of 1-2.

### Reply 4

We have updated the Figure legends to have capital rather than lower case letters. We have removed the labeling “2-1” and “2-2” from the CARE checklist document. (ACR-23-86 FigureLegends.docx and ACR-23-86 Revised\_CARE checklist.pdf)

### **Reviewer B**

1. Please check if any reference should be added since you mention “studies”.
  - Dosing followed prior published **studies** with gemcitabine given at 1000 mg/m<sup>2</sup>, paclitaxel-protein bound at 125 mg/m<sup>2</sup>, and cisplatin at 25 mg/m<sup>2</sup> [7].
  - The patient did not have any tolerability issues outside of prior published **studies** that were unexpected [7].

### Reply:

The corresponding reference for this information is #7, which is cited at the end of this sentence. No additional references are needed. We have changed the word “studies” in both sentences to “literature” to avoid confusion.

### Change to the text:

p.4, lines 114-116:

“Dosing followed prior published **literature** with gemcitabine given at 1000 mg/m<sup>2</sup>, paclitaxel-protein bound at 125 mg/m<sup>2</sup>, and cisplatin at 25 mg/m<sup>2</sup> (7).”

p.4-5, lines 118-119:

“The patient did not have any tolerability issues outside of prior published **literature** that were unexpected (7).”